US 11,667,673 B2
Therapeutically active compounds and their methods of use
Janeta Popovici-Muller, Windham, NH (US); Rene M. Lemieux, Charlestown, MA (US); Jeremy Travins, Southborough, MA (US); Zhenwei Cai, Princeton, NJ (US); Dawei Cui, Shanghai (CN); and Ding Zhou, Shanghai (CN)
Assigned to Servier Pharmaceuticals LLC, Boston, MA (US)
Filed by Servier Pharmaceuticals LLC, Boston, MA (US)
Filed on Jun. 5, 2020, as Appl. No. 16/893,750.
Application 16/893,750 is a continuation of application No. 16/427,691, filed on May 31, 2019, granted, now 10,717,764.
Application 16/427,691 is a continuation of application No. 15/809,325, filed on Nov. 10, 2017, granted, now 10,640,534, issued on May 5, 2020.
Application 15/809,325 is a continuation of application No. 15/279,146, filed on Sep. 28, 2016, granted, now 9,850,277, issued on Dec. 26, 2017.
Application 15/279,146 is a continuation of application No. 13/745,005, filed on Jan. 18, 2013, granted, now 9,474,779, issued on Oct. 25, 2016.
Prior Publication US 2021/0024575 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 401/04 (2006.01); A61P 35/00 (2006.01); C07K 5/065 (2006.01); C07D 207/26 (2006.01); C07D 205/08 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); A61K 38/00 (2006.01); C07K 5/06 (2006.01); C07D 401/12 (2006.01)
CPC C07K 5/06078 (2013.01) [A61K 38/005 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); C07D 205/08 (2013.01); C07D 207/26 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 401/12 (2013.01); C07K 5/06191 (2013.01)] 3 Claims
 
1. A method of treating myelodysplastic syndrome (MDS) characterized by having an IDH1 mutation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or hydrate thereof.